kevin joo

Huge news today at Isomorphic Labs! We have secured $2.1 Billion investment to advance the most important mission that AI can unlock: to change the way we can improve human health and create new medicines for patients around the world. This funding milestone was built on the strength of our AI drug design engine (IsoDDE), which has already proven its worth (aside from smashing benchmarks) by designing breakthrough new molecules and creating new scientific breakthroughs across our drug discovery programs. Our IsoDDE is giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that we couldn’t unlock until now. A massive thank you to our incredible team across London, Boston and Lausanne, whose relentless work made this possible, and to our partners who share our ultimate vision. Now we have so much more to build together!

@lobotomy_user @blockchainz555 @rasmr_eth madison fare over myka? have not tried either mimi's is ass

@blockchainz555 @rasmr_eth yeah i agree madison fare is the best

first date idea in nyc: stand in a frozen yogurt line for 40 minutes while petting her head and whispering “trust me this usually moves way faster” in her ear over and over again

if you showed me this a year ago i would have laughed in your face

cursor, replit, many others overlooked probs even langchain, never doubt enterprise contracts

the forced dutch auction

SF guy eating a delicious blueberry: in 18 months everything will be blueberries

Thanks to good people at @AnthropicAI we now have an official MCP for Excalidraw! Take it for a spin on @claudeai (search for Excalidraw in Connectors, or use in Claude Code and elsewhere). More to come. ✌

@Slokh @dwr @tempo lfg

Working on @tempo now 🫡

Dexter hit 10,000 stars on GitHub. It’s OpenClaw and Claude Code, for finance. What Dexter can do: • find undervalued stocks • break down financials • turn research into a thesis All our code is open source.

"Opus 4.6 just figured out a product, how to position and market it, why it defeats competitors, all in one prompt" ok then why haven't you sold any the last ten times you did this

Introducing Claude Opus 4.6. Our smartest model got an upgrade. Opus 4.6 plans more carefully, sustains agentic tasks for longer, operates reliably in massive codebases, and catches its own mistakes. It’s also our first Opus-class model with 1M token context in beta.

finally they improved it before my codex prompt from last week finished

@jermdemo have you tried any of them?

OK, so the $ bio ai assistants are: Ascent Bio - ascentbio.ai Bio Protocol BIOS - ai.bio.xyz Edison Scientific - edisonscientific.com K-Dense - k-dense.ai Potato - potato.ai SciSpace - scispace.com/biomedical/ Did I miss any?

snow in NYC is pretty crazy right now but luckily i managed to go to the grocery store before everything ran out

Announcing our latest open medical AI models for developers: MedGemma 1.5, which is small enough to run offline & improves performance on 3D imaging (CT & MRI), & MedASR, a speech-to-text model for medical dictation. Both available on Hugging Face + Vertex AI. goo.gle/3L9oiII #MedGemma #HealthAI #GenerativeAI

@machines_cash hell yea congrats

launch machines alpha release is live in the US 📲 control your spending with alias accounts and virtual cards. deposit bitcoin, monero, zcash, solana, tron, usdt, usdc, ethereum and evm assets. spend anywhere visa is accepted. 👀 get started now app.machines.cash

Science is too slow. At Edison, we are integrating AI Scientists into the full stack of research, from basic discovery to clinical trials. We want cures for all diseases by mid-century. We have raised a $70M seed to get started. Join us. We need cracked software engineers who want to work on finding cures rather than selling ads and generating slop. If you’re reading this, you’re probably a candidate. We need brilliant AI researchers who want to figure out how AI will accelerate real-world science. We need scientists and researchers with deep expertise in biology, biotech, and pharma who want to figure out how to integrate AI deeply into scientific workflows, from ideation to experimentation, and how to measure success or failure. We need extraordinarily talented generalist operators across BD, sales, product management, and partnerships who can focus on getting our tools into the hands of pharmaceutical companies. If any of these roles sound like you, get in touch. We are also expanding access to our platform. Our goal is to accelerate science writ large. To that end, we will continue to give academics and students 650 credits/mo indefinitely. I can’t promise we’ll keep this up forever, but we will try. Kosmos will still cost 200 credits, and the other agents (Analysis, Literature, etc.) will cost 1 or 2 credits. All paid users will have access to our regular agents, like our Analysis agent, Literature agent, and so on, for free via the UI. API access will still be paid, and users without a paid subscription will continue to get 10 credits per month for those agents. Our $200/mo subscription for 650 credits/mo is staying in place for now, but might be phased out at our next major product update. Along the lines of accelerating science, we’re also doing a major release of PaperQA today, our flagship open source literature agent, as part of our commitment to open science. In the short run, expect major improvements to Kosmos, including the ability to automatically access data, the ability to steer its exploration, and the ability to converse directly with its world model. In the long run, expect exponentially increasing rates of scientific discoveries, in biology and elsewhere. Our round is led by Triatomic Capital, Spark Capital, and a major US institutional biotech investor. We are also joined in this round by existing investors Pillar VC and Susa Ventures, two exceptional early-stage funds who backed us at founding, along with Striker Venture Partners, Hawktail VC, Olive VC, and a host of exceptional angels that includes famous AI researchers, the CEOs of multiple frontier AI labs, and leadership of major biotech and pharma companies.

@CoughdropPeter ultra rare sandshrew

“Some people have already started to realize that using prediction markets can be cheaper than conventional fire, flood, and hurricane insurance.” - Vlad, Robinhood